Cover Image
市場調查報告書

Smoothened Homolog (Protein Gx or SMO) :開發中產品分析

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365789
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
Smoothened Homolog (Protein Gx or SMO) :開發中產品分析 Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 78 Pages
簡介

本報告提供以Smoothened Homolog (Protein Gx or SMO) 為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

Smoothened Homolog (Protein Gx or SMO) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • BeiGene, Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Ignyta, Inc.
  • Mayne Pharma Group Limited
  • Novartis AG
  • PellePharm, Inc.
  • Pfizer Inc.
  • Redx Pharma Plc
  • Stemline Therapeutics, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0263TDB

Summary

Global Markets Direct's, 'Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016', provides in depth analysis on Smoothened Homolog (Protein Gx or SMO) targeted pipeline therapeutics.

The report provides comprehensive information on the Smoothened Homolog (Protein Gx or SMO), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
  • The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Smoothened Homolog (Protein Gx or SMO) Overview
  • Therapeutics Development
    • Smoothened Homolog (Protein Gx or SMO) - Products under Development by Stage of Development
    • Smoothened Homolog (Protein Gx or SMO) - Products under Development by Therapy Area
    • Smoothened Homolog (Protein Gx or SMO) - Products under Development by Indication
  • Smoothened Homolog (Protein Gx or SMO) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Smoothened Homolog (Protein Gx or SMO) - Products under Development by Companies
  • Smoothened Homolog (Protein Gx or SMO) - Products under Development by Universities/Institutes
  • Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development
    • BeiGene, Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Ignyta, Inc.
    • Mayne Pharma Group Limited
    • Novartis AG
    • PellePharm, Inc.
    • Pfizer Inc.
    • Redx Pharma Plc
    • Stemline Therapeutics, Inc.
  • Smoothened Homolog (Protein Gx or SMO) - Drug Profiles
    • glasdegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSA-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itraconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LEQ-506 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Smoothened for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • patidegib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RDX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Smoothened (Smo) Receptor for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Smoothened Homolog for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sonidegib phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • taladegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vismodegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Smoothened Homolog (Protein Gx or SMO) - Dormant Projects
  • Smoothened Homolog (Protein Gx or SMO) - Discontinued Products
  • Smoothened Homolog (Protein Gx or SMO) - Featured News & Press Releases
    • Jun 02, 2016: Curis Announces Presentations Related to Erivedge at 2016 ASCO Annual Meeting
    • Jun 02, 2016: FDA Grants Orphan Drug Designation to SUBA-Itraconazole for Treatment of Patients with BCCNS
    • Sep 29, 2015: HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial
    • Aug 21, 2015: HedgePath Pharmaceuticals Launches Clinical Trial for its Proposed Cancer Treatment
    • Aug 20, 2015: Novartis drug Odomzo gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients
    • Jul 24, 2015: FDA approves Novartis drug Odomzo (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
    • May 20, 2015: Curis Announces Presentations of Erivedge Clinical Data at 2015 ASCO Annual Meeting
    • May 18, 2015: New Equity Investment In Hedgepath Pharmaceuticals Ahead Of Commencing Phase IIB Trial With Suba-Itraconazole In Skin Cancer
    • Mar 09, 2015: Skin tumors develop specific mutations to resist drug, researchers say
    • Mar 02, 2015: Basal Cell Carcinoma Drug Encourages Both Cancer Regression and Loss of Taste in Patients
    • Dec 16, 2014: HedgePath Pharmaceuticals Receives IND Clearance to Commence Development of its Proposed Cancer Treatment
    • Nov 18, 2014: HedgePath Pharmaceuticals Files IND Application
    • Sep 17, 2014: Novartis presents oncology research advances with new data on sonidegib at ESMO 2014
    • Jun 23, 2014: Curis Announces Investigational New Drug Application Filing by Roche to Initiate a Phase II Study of Erivedge (vismodegib) in Idiopathic Pulmonary Fibrosis
    • Jun 01, 2014: Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by BeiGene, Ltd., H1 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Pipeline by Ignyta, Inc., H1 2016
  • Pipeline by Mayne Pharma Group Limited, H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by PellePharm, Inc., H1 2016
  • Pipeline by Pfizer Inc., H1 2016
  • Pipeline by Redx Pharma Plc, H1 2016
  • Pipeline by Stemline Therapeutics, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Dormant Projects (Contd..3), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top